Honeywell International’s Alexion Pharmaceuticals ALXN Stock Holding History

Honeywell International’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-128,000	Closed	-$12.5M	–	149
2018 Q4	$12.5M	Buy	128,000 +400	+0.3%	+$47.3K	0.82%	46
2018 Q3	$17.7M	Buy	127,600 +37,900	+42%	+$4.75M	1.01%	32
2018 Q2	$11.1M	Sell	89,700 -33,000	-27%	-$3.86M	0.67%	62
2018 Q1	$13.7M	Sell	122,700 -106,800	-47%	-$12.8M	0.8%	54
2017 Q4	$27.4M	Buy	229,500 +40,100	+21%	+$4.88M	0.91%	48
2017 Q3	$26.6M	Buy	189,400 +100	+0.1%	+$13.6K	0.93%	45
2017 Q2	$23M	Hold	189,300	–	–	0.87%	43
2017 Q1	$23M	Sell	189,300 -56,400	-23%	-$7.27M	0.74%	48
2016 Q4	$30.1M	Buy	245,700 +69,700	+40%	+$8.53M	1.01%	26
2016 Q3	$21.6M	Buy	+176,000	New	+$22.7M	0.75%	44

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Honeywell International's ALXN Position: Q1 2019 in Review

Honeywell International sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 128,000 shares — an estimated $12.5M sold.

Honeywell International first reported a position in ALXN in Q3 2016 and held it in 10 quarters. The position peaked at $30.1M in Q4 2016. 612 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Honeywell International reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Honeywell International sold 128,000 Alexion Pharmaceuticals shares in Q1 2019, an estimated $12.5M.
Honeywell International first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 10 quarters.
Honeywell International's Alexion Pharmaceuticals position peaked at $30.1M in Q4 2016.
612 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Honeywell International's 13F filing for Q1 2019, filed 2 May 2019.